RARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year End

Key Takeaways RARE and MREO fell after delaying new data from the phase III UX143 Orbit study to year-end. The Orbit study continues as planned, with final data expected by the end of 2025. Interim safety review found UX143 acceptable, allowing studies to proceed without changes.Ultragenyx Pharmaceutical (RARE) and partner, Mereo BioPharma (MREO) , have reported an update on the progress of the mid-to-late-stage Orbit study, which is evaluating UX143 (setrusumab) for the treatment of osteogenesis imperfec ...